PLSE trades 13.5% below Wall Street's consensus target of $60.20.
Last 12 months price action with 12-month analyst target path
The base valuation assumes PLSE achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 24, 2026, Pulse Biosciences, Inc. (PLSE) has a Wall Street consensus price target of $60.20, based on estimates from 6 covering analysts. With the stock currently trading at $53.02, this represents a potential upside of +13.5%. The company has a market capitalization of $3.67B.
Analyst price targets range from a low of $55.00 to a high of $70.00, representing a 25% spread in expectations. The median target of $58.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, PLSE trades at a trailing P/E of -49.1x. Analysts expect EPS to grow -2.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 INVAInnoviva, Inc. | $1.5B | $20.66 | $38.00 | +83.9% | Buy | 8.5x | 10 |
 NVCRNovocure Ltd | $1.7B | $14.68 | $26.00 | +77.1% | Buy | — | 15 |
 ATECAlphatec Holdings, Inc. | $1.7B | $11.11 | $16.22 | +46.0% | Buy | 34.0x | 20 |
 ANABAnaptysBio, Inc. | $1.4B | $48.73 | $79.17 | +62.5% | Buy | 9.6x | 23 |
 INMDInMode Ltd. | $803M | $13.97 | $19.00 | +36.0% | Hold | 10.8x | 11 |
 MDTMedtronic plc | $122.5B | $95.41 | $97.73 | +2.4% | Buy | 16.0x | 51 |
 BSXBoston Scientific Corporation | $67.9B | $45.69 | $59.55 | +30.3% | Buy | 14.1x | 44 |
 ABTAbbott Laboratories | $180.6B | $103.70 | $121.36 | +17.0% | Buy | 18.8x | 43 |
 SYKStryker Corporation | $117.7B | $307.15 | $365.89 | +19.1% | Buy | 20.5x | 52 |
 ISRGIntuitive Surgical, Inc. | $159.8B | $452.29 | $485.44 | +7.3% | Buy | 40.4x | 57 |
Quick answers to the most common questions about buying PLSE stock.
Pulse Biosciences, Inc. (PLSE) has a consensus 12-month price target of $60.2, implying 13.5% upside from $53.02. The 6 analysts covering PLSE see moderate appreciation potential.
PLSE has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $60.2 implies 13.5% upside from current levels.
PLSE's current price is $53.02 with a consensus target of $60.2 (13.5% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $70 for PLSE, while the most conservative target is $55. The consensus of $60.2 represents the median expectation. These targets typically reflect 12-month expectations.
PLSE is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PLSE stock forecast based on 6 Wall Street analysts shows a consensus price target of $60.2, with estimates ranging from $55 (bear case) to $70 (bull case). The median consensus rating is "Buy".
Wall Street analysts are optimistic on PLSE, with a "Buy" consensus rating and $60.2 price target (13.5% upside). 4 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PLSE analyst price targets range from $55 to $70, a 25% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $60.2 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.